Background:
Diabetes mellitus is the most common disease in Egypt. In this context, Beta
vulgaris subspecies cicla L. var. flavescens is an edible plant that has been used in traditional medicine
as a therapy for treating some diseases.
Objective:
The current study was performed to evaluate the antibacterial and potential anti-diabetic
activities of different extracts and isolated flavone C-glycoside compounds isolated from Beta vulgaris
subspecies cicla L. var. flavescens leaves.
Methods:
Phytochemical investigation of n-butanol extract led to the isolation of five phytoconstituents.
Their structures were determined by spectroscopic tools, including 1D-NMR (1H- & 13C-NMR)
and 2D-NMR (HMQC & HMBC) besides the comparison of the data with the literature. The extracts
and phytoconstituents were evaluated in vitro for their activity against some bacterial pathogens, which
represent prominent human pathogens, particularly in hospital settings. The antibacterial activity was
examined against three Gram-positive bacterial strains (Staphylococcus aureus, Staphylococcus epidermidis
& Enterococcus faecalis) and five Gram-negative ones (Pseudomonas aeruginosa, Proteus
vulgaris, Klebsiella pneumoniae, Proteus mirabilis & Salmonella typhimurium) relative to Ciprofloxacin
as a reference drug. Furthermore, the in vitro antidiabetic activity (Type II) was evaluated using the
alpha-glucosidase inhibitory assay.
Results:
Five flavone C-glycosides namely; Apigenin 8-C-β-D-glucopyranoside (vitexin) (1), 2''-Oxylopyranosylvitexin
(2), acacetin 8-C-β-D-glucopyranoside (3), acacetin 8-C-α-L-rhamnoside (4), and
6,8-di-C-β-D-glucopyranosylapigenin (vecinin-II) (5) were isolated from n-butanol extract of B. vulgaris
subspecies cicla L. var. flavescens. Compound 1 showed a promising antibacterial activity
against most of the test bacterial strains with respect to the minimum inhibitory concentration values
(MIC) ranged from 1.95 to 15.63 µg ml-1. On the other hand, compounds 1 and 3 demonstrated superior
antidiabetic activities with IC50 values of 35.7 and 42.64 µg ml-1, respectively, while an inferior potential
antidiabetic activity was recorded for compound 4 (IC50 = 145.5 µg ml-1) in comparison with
Acarbose as a reference drug.
Conclusion:
B. vulgaris L. is an edible plant, which could be used as a natural source of antibiotic and
hypoglycemic drugs.
The study was designed to evaluate the effects of rice bran (RB) or its oil (RBO) on lipid metabolism, hepatic insulin receptor substrate‐1 (IRS‐1) and hepatic expression of 3‐hydroxy‐3‐methylglutaryl‐Co A (HMG‐CoA) reductase in rats fed high‐fructose diet (HFD). Rats were divided into four groups: Group 1, animals received standard diet as control, while groups 2, 3 and 4 were fed on a HFD. Groups 3 and 4 animals fed HFD containing RB (5%) instead of cellulose and RBO (10%) instead of corn oil, respectively for 5 weeks. Fructose feeding to rats caused significant elevations in plasma glucose, serum insulin, and lipid profile, while serum total antioxidant capacity was significantly reduced compared to control. Hepatic concentration of IRS‐1 was decreased while malondialdehyde (MDA) and HMG‐CoA reductase mRNA were elevated compared to control group. Addition of RB or RBO to fructose fed rats alleviated the hazardous effects of fructose.
Practical applications
Rats fed high‐fructose diet were used as a model of insulin resistance accompanied by deleterious metabolic consequences including hyperinsulinemia, hyperglycemia, glucose intolerance, hypertriglyceridemia and hypertension in rats and these metabolic effects are similar to those observed in human multi‐metabolic syndrome X. Supplementation of rice bran or rice bran oil to fructose‐fed rats improves insulin resistance and reduces lipo‐ and glucotoxicity.
In the present study, the effects of subchronic treatments (4 weeks) of hypercholesterolemic (single) and diabetic-hypercholesterolemic (combined) rats with 4 (3H) quinazolinone and 2 halogenated derivatives (6, 8-dibromo-2-methy-4 (3H) quinazolinone and 6-iodo-2-methyl-4(3H) quinazolinone) at a sublethal dose level (2 mg/Kg) on cholesterol metabolism were investigated. Bezafibrate, a hypolipidemic drug was used as a reference compound for data comparison. Treatment of rats with single and combined hypercholesterolemia with quinazolinone compounds gave rise to highly significant reductions in serum total cholesterol and cholesterol ester levels, whereas serum triacylglycerol level was significantly reduced only after treatment with halogen-substituted quinazolinones in single hyper-cholesterolemia, compared to the control group. The effects of different quinazolinones and bezafibrate on reduction of serum LDL-C level were comparable in single hypercholesterolemia but significantly different in combined hypercholesterolemia. Results obtained from this study suggest that the antihyperlipidemic effect of quinazolinone compounds was brought about by inhibition of dietary cholesterol absorption and / or intestinal ACAT activity.
From the leaves of Duranta repens (Verbenaceae) two new triterpene saponins, named durantanin IV (1) and V (2) were isolated. In addition, ten known compounds were isolated, namely a bidesmosidic saponin, oleanolic acid, three phenylethanoids and five flavonoids. All metabolites were isolated for the first time from this genus except for 3 (oleanolic acid) and 7 (E/Z acteoside). The structures were determined mainly by spectroscopic methods (UV, IR, HRESI-MS, 1H-, 13C-NMR, 1H-1H COSY, HSQC and HMBC). Cytotoxic screening of the chloroform, ethyl acetate and methanol extracts was carried out on brine shrimps. In addition, the investigated methanol extract and compounds 1, 2 and 7 showed significant cytotoxic activity against a HepG2 cell line.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.